RxDoctor Payments Data

Angela Ullon

Physician Assistant · Pace, FLNPI 1639379357

Payments from drug & device makers

$2,038in general payments, 2019–2025

Across 91 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$657
  • AbbVie$324
  • AstraZeneca$310
  • Phathom Pharmaceuticals, Inc.$259
  • Lilly USA, LLC$76
  • Merck$76
  • plus $337 from 10 others

What the payments were for

  • Food & beverage$2,038100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,038 in reported general payments places this provider in the 75th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$52,378
Medicare patients
172
Services billed
897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$63,853
MounjaroTirzepatide33$42,663
EliquisApixaban17$14,170
Tresiba Flextouch U-200Insulin Degludec13$12,565
JardianceEmpagliflozin12$12,495
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,706
VascepaIcosapent Ethyl12$6,227
Albuterol Sulfate HfaAlbuterol Sulfate67$2,308
Varenicline Tartrate15$1,567
Gabapentin80$1,559
Atorvastatin Calcium102$1,192
Pantoprazole Sodium62$1,141
Omeprazole87$991
Duloxetine Hcl35$961
Levothyroxine Sodium104$928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$657$63,85370 claims
Lilly USA, LLCMounjaro$76$42,66333 claims
PfizerEliquis$17$14,17017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Pace

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →